Home About Cancer News Contact Cancer News
Home About Cancer News Contact Cancer News
Twitter

Posts Tagged ‘nci’

« Older Entries
Newer Entries »

NIH Research Radio: A Clinical Trial for HIV-Positive Cancer Patients

By on Wednesday, November 14th, 2012 | No Comments

NCI Cancer Bulletin writer and editor Daryl McGrath talks about a phase II clinical trial exploring the safety of stem cell transplants for HIV-positive cancer patients

Read More...

MD Anderson study finds patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway

By on Friday, November 9th, 2012 | No Comments

Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes’ pathways of action, according to research from the MD Anderson Cancer Center presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

Read More...

In Advanced Solid Tumors, New Monoclonal Antibody Inhibits Tumor Growth In Phase I Clinical Trial

By on Thursday, November 8th, 2012 | No Comments

A newly developed antibody targeting a signalling pathway that is frequently active in solid tumours has shown encouraging signs of efficacy in its first trial in humans, researchers reported at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland…

Read More...

Wake Forest study finds some cancer survivors report poor health-related quality of life years after diagnosis

By on Thursday, November 1st, 2012 | No Comments

Survivors of many common cancers enjoy a mental and physical health-related quality of life equal to that of adults who have not had cancer, but survivors of other cancers are in poorer health, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Researchers from the Wake Forest Baptist Medical Center, home to the Wake Forest Comprehensive Cancer Center, and from the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) analyzed data from the 2010 National Health Interview Survey, a large survey conducted by the CDC to track trends in illness and disability in the United States. They identified a cohort of 1,822 cancer survivors and compared them with 24,804 adults with no history of cancer.

Read More...

HIV infection connected to rising anal cancer rates in men in the U.S.

By on Wednesday, October 10th, 2012 | No Comments

Human immunodeficiency virus (HIV) infection contributes substantially to the epidemic of anal cancer in men, but not women in the United States, according to new research from NCI. Chart shows overall incidence rates of anal cancers in general population with dashed line showing those with HIV infection.

Read More...

Gene variant linked to lung cancer risk

By on Wednesday, October 10th, 2012 | No Comments

A variation of the gene NFKB1, called rs4648127, is associated with an estimated 44 percent reduction in lung cancer risk. When this information, derived from samples obtained as part of a large NCI-sponsored prevention clinical trial, was compared with data on a different sample collection from NCI’s genome-wide association studies (GWAS), lung cancer risk was still estimated to be lower, but only by 21 percent.

Read More...

NCI Director Discusses "What Impedes Cancer Research"

By on Wednesday, October 3rd, 2012 | No Comments

On September 25, NCI Director Dr. Harold Varmus spoke at the National Press Club about the barriers that hinder the nation’s ability to make faster progress against cancer.

Read More...

Commentary: Statement on Breast Cancer Awareness Month

By on Wednesday, October 3rd, 2012 | No Comments

The Honorable Kathleen Sebelius is the 21st secretary of the Department of Health and Human Services, which includes NCI. Secretary Sebelius released the following statement to mark Breast Cancer Awareness Month.

Read More...

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery

By on Friday, September 21st, 2012 | No Comments

Conditions :   Childhood Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma Interventions :   Drug: tivantinib;   Drug: erlotinib hydrochloride Sponsors :   National Cancer Institute (NCI);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...

A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma

By on Friday, September 21st, 2012 | No Comments

Conditions :   Micropapillary Cancer of the Bladder;   Squamous Cell Carcinoma of the Bladder;   Bladder Cancer With Bone Metastases;   Bladder Cancer;   Small Cell Cancer of the Bladder;   Urachal Cancer;   Sarcomatoid Bladder Cancer Interventions :   Drug: Cabozantinib;   Procedure: FDG PET CT;   Procedure: NaF PET CT Sponsors :   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...
« Older Entries
Newer Entries »